Teva Pharmaceuticals

TEVA

Market cap $36.4B

ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the New England Journal of Medicine (NEJM) has published pivotal Phase 3 data on AJOVY, highlighting its efficacy and safety in children and adolescents with episodic migraine. The data from the SPACE study supported the FDA approval of AJOVY for the preventive treatment of episodic migraine in pediatric patients aged 6-17 years weighing 45 kilograms (99 pounds) or more, making it the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for preventive treatment of episodic migraine in pediatric patients and migraine in adults.1,2

Teva Pharmaceutical (TEVA) remains a Buy, with specialty drugs, margin expansion, and the Royalty Pharma partnership driving further upside despite a 112% rally. TEVA's specialty pipeline—AUSTEDO, UZEDY, AJOVY—now anchors growth, with Royalty Pharma's $500M backing validating R&D and enabling non-dilutive financing. At under 12x 2026 earnings, TEVA trades below specialty pharma peers; a rerating to 14x could yield 19–30% further upside if execution continues.

Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-‘408.

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

Teva Pharmaceuticals stock jumped Monday after the drugmaker issued upbeat guidance and targets for the years ahead.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)